ChemoCentryx Inc. (NASDAQ:CCXI) shares rose 10.4% during trading on Tuesday . The stock traded as high as $5.17 and last traded at $5.11, with a volume of 276,654 shares. The stock had previously closed at $4.63.

Separately, JPMorgan Chase & Co. reiterated a “buy” rating and set a $11.00 price target on shares of ChemoCentryx in a report on Tuesday, August 9th.

The stock has a 50 day moving average price of $4.57 and a 200 day moving average price of $3.97. The firm’s market capitalization is $240.00 million.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geduld E E acquired a new position in shares of ChemoCentryx during the second quarter worth $112,000. Landscape Capital Management L.L.C. acquired a new position in shares of ChemoCentryx during the first quarter worth $113,000. Alliancebernstein L.P. acquired a new position in shares of ChemoCentryx during the second quarter worth $142,000. Bank of Montreal Can acquired a new position in shares of ChemoCentryx during the second quarter worth $144,000. Finally, Emerald Acquisition Ltd. acquired a new position in shares of ChemoCentryx during the second quarter worth $155,000. 47.79% of the stock is currently owned by hedge funds and other institutional investors.

About ChemoCentryx

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

5 Day Chart for NASDAQ:CCXI

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.